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Abstract—This paper presents a multi-functional automatic
control approach for total intravenous anesthesia (TIVA) admin-
istration, valid for several drug combinations and able to run
autonomously during the three main phases of general anesthesia:
induction, maintenance and recovery. While using this standalone
TIVA module, named as amTIVA, the anesthesiologist has the
crucial role of system supervisor. Bolus administration, open-
loop target controlled infusion (TCI) and closed-loop controlled
infusion modes are implemented and available for the control
of the two main components of anesthesia: the neuromuscular
blockade and the depth of anesthesia. This multi-functional
module is implemented in the GALENO Platform and was
successfully tested in more than thirty clinical cases.
I. INTRODUCTION
Total intravenous anesthesia (TIVA) is a technique of gen-
eral anesthesia where all the anesthetic drugs are intravenously
administered. During the induction phase the patient is brought
to a reversible state of hypnosis, analgesia and muscle re-
laxation through the administration of hypnotics, analgesics
and muscle relaxants. After induction, during the maintenance
phase, the patient must remain in the anesthetic condition
adequate for the surgery. The recovery phase occurs after
the cessation of administration of the intravenous drugs and
enables the return to baseline physiologic functions.
Mainly driven by the potential of automation in several
applications [1], the subject of automation in anesthesia has
focused the efforts of many research teams worldwide during
the last decades. Despite the great progress that has occurred,
the day when the anesthesiologist is replaced completely
by a machine is still unforeseeable. In spite of the several
sophisticated devices that exist nowadays in the operating
room, the anesthesiologist is still the sole player in the process
of defining the amount of drugs to be administered to the
patients so that the physiologic variables that are measured
from the patient follow the pre-defined references or lay inside
the admissible physiologic ranges.
This paper presents a multi-functional automatic control ap-
proach for TIVA administration, named as amTIVA, in which
the anesthesiologist becomes supervisor of the whole process.
This constitutes the first contribution of the paper. The whole
strategy is implemented within the GALENO Platform [2] and
incorporates several controllers for the two main components
of anesthesia: the neuromuscular blockade (NMB) and the
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Fig. 1: Structure of the multi-functional automatic controller
amTIVA as implemented in the GALENO Platform.
depth of anesthesia (DoA). A schematic representation of the
whole system is shown in Fig. 1. The second contribution of
the paper is the development of a novel and heuristic approach
for Target Controlled Infusion (TCI) for the DoA, hereafter
referred as GALENO-TCI. The third contribution of the paper
is the assessment of the performance of the amTIVA for the
control of the NMB and the DoA in more than thirty real cases
of general anesthesia.
The remainder of this paper is organized as follows. Section
II describes the system architecture and the basic concepts
behind the NMB and BIS measurements. Section III presents
three control algorithms for the induction and maintenance of
anesthesia. Section IV shows the results obtained when the full
control strategy was used in the clinical setting and section V
draws the conclusions.
II. SYSTEM SETUP: SENSORS AND MODULE
ARCHITECTURE
A. NMB and BIS measurements
A commonly used method to monitor the NMB is by using
of the first response (T1%) of a Train-of-Four (TOF) electrical
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stimulation of the ulnar nerve at the patient’s hand calibrated
by a reference twitch [3].
The hypnotic component of the DoA can be evaluated by the
bispectral index (BIS) [4], a multi-factorial parameter derived
from the electroencephalogram. The BIS is a dimensionless
number that varies from 0 (corresponding to total suppression
of cortical electrical activity) to 97.7 (corresponding to full
cortical electrical activity). A BIS between 40 and 60 is
associated with a low probability of intra-operative awakening
and awareness, and is recommended for general anesthesia.
The appropriate measurement of the TOF and BIS responses
is a requisite for the proper performance of the whole control
strategy. Hence, the specifications for placement of the elec-
trodes and sensors as established by manufacturers should be
strictly followed.
B. Automated module for TIVA (amTIVA)
Figure 2 shows the graphic user interface of the amTIVA
module developed for the automated TIVA administration.
The flowchart of the amTIVA was inspired by the work in
[5] and was further extended to the induction phase. The
amTIVA works at a higher level by managing the NMB control
module and the DoA/BIS control module, and it incorporates
the followings features to facilitate the sequentiality between
the three anesthesia phases, thereby increasing its practical
clinical performance:
1) The anesthesiologist configures the amTIVA based on
the anesthetic protocol, setting the adequate drugs:
analgesic (remifentanil, sufentanil or fentanil), hyp-
notic (propofol) and muscle relaxant (rocuronium or
atracurium).
2) The anesthesiologist selects, through the amTIVA in-
terface, the following types of analgesic and hypnotic
drugs administration: i) target controlled infusion (TCI),
ii) bolus in µ/kg or iii) pre-defined continued infusion
rate in ml/h. It should be noted that constraints were
added to the interface so that fentanil is only manually
delivered. Moreover, due to clinical constraints during
the induction phase the muscle relaxant can only be
administered by bolus.
The amTIVA also includes:
• A button to manual clinical validation of the NMB sensor
calibration (“NMB S.Cali-OKt’t’).
• A button indicating the completion of the intubation and
the end of the induction phase (“Intubation-OKt’t’).
III. CONTROL STRATEGIES
A. Induction phase
The induction phase of general anesthesia is characterized
by the administration of high doses of anesthetics to the
patients, aiming at reaching a reversible state of hypnosis, anal-
gesia, and muscle relaxation in a short time. The recommended
amount of each anesthetic drug for induction follows popula-
tion studies and is well defined for each clinical case. Since it
is very difficult to predict accurately the pharmacokinetic (PK)
Fig. 2: GUI of the automated control module for TIVA
(amTIVA). The combination of remifentanil, propofol and
rocuronium is here used as an example.
and pharmacodynamic (PD) response of each patient to these
predefined population doses, the amTIVA is defined such that,
during the induction phase and until the patient’s physiologic
signals had stabilized, the anesthetic drugs are administered
by bolus or by open-loop controllers as TCI, instead of by
closed-loop controllers.
1) Neuromuscular blockade: Due to clinical restrictions
the induction of the NMB is always performed through an
initial bolus administration. Even though being automatically
administered by the syringe pumps, the amount and infusion
rate of the muscle relaxant drug has to be defined in the “INF.
Rocuroniumt’t’ block in Fig. 2.
2) Depth of anesthesia: The induction phase of DoA may
be performed through different protocols as explained in sec-
tion II-B. In this subsection the novel and heuristic approach
GALENO-TCI that is proposed in this paper is described.
The main idea of TCI is to use a predefined population
PK/PD model to determine the plasma or/and effect site
concentration, and to compute the amount of drug needed to
reach the target concentration by ”inversion” of the model.
The GALENO-TCI is a heuristic predictive TCI algorithm
that uses the compartment PK/PD models in [6], [7], [8], [9]
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Fig. 3: Representation of parametric tri-compartmental PK
model plus the effect compartment.
for propofol, remifentanil and sufentanil, as predictive models.
Figure 3 shows a general scheme of these tri-compartmental
models, being its mathematical representation [10] given by
dC1
dt
=
IR  (k10 + k12 + k13)V1C1 + k21V2C2 + k31V3C3
V1
(1a)
dC2
dt
=
k12V1C1   k21V2C2
V2
(1b)
dC3
dt
=
k13V1C1   k31V3C3
V3
(1c)
dCE
dt
= ke0C1   ke0CE (1d)
where:
kij is the transfer rate from compartment i to j [min 1];
Vi is the volume of the compartment i [ml];
C1 is the plasma concentration [QD1/ml];
C2, C3 are the peripheral compartment concentrations
[QD/ml];
CE is the effect site concentration [QD/ml];
IR is the drug infusion rate [QD/min].
For the digital implementation of the GALENO-TCI, the
continuous time equations (1) were transformed to discrete
time (2) using the zero-order hold method (see e.g. [11]) and
sampling time Ts as
C1[n+ 1] =
✓
IR[n]  (k10 + k12 + k13)V1C1[n]
V1
◆
Ts+✓
k21V2C2[n  1] + k31V3C3[n]
V1
◆
Ts + C1[n] (2a)
C2[n+ 1] =
✓
k12V1C1[n]  k21V2C2[n]
V2
◆
Ts + C2[n] (2b)
C3[n+ 1] =
✓
k13V1C1[n]  k31V3C3[n]
V3
◆
Ts + C3[n] (2c)
CE[n+ 1] = (ke0C1[n]  ke0CE[n])Ts + CE[n] (2d)
When the target of the TCI strategy is the plasma con-
centration C1, the controller determines the value IR[n] that
1QD is the notation to represent the quantity of drug (ng, µg, mg), this
must be the same for the compartment concentration that for the infusion rate
matches C1 with the reference or target concentration CT and
the solution is obtained by substituting (3) in (2a), and solving
for IR[n] as
C1[n+ 1] = CT (3)
IR[n] =
(CT   C1[n])V1
Ts
+ (k10 + k12 + k13)V1C1[n]
  k21V2C2[n]  k31V3C3[n] (4)
where (4) is subject to
0  IR[n]  IRmax (5)
When the target of the TCI strategy is the effect site
concentration CE, the problem increases in complexity. The
controller must determine the value of IR[n] that matches
C1, CE and CT (6). The first step to obtain the solution is
by substituting (6) and (2a) in (2d) and solving for IR[n] as
CE[n+ 1] = C1[n+ 1] = CT (6)
IR[n] = V 1
 
CT CE[n]
ke0Ts
+ CE[n]  C1[n])
Ts
!
+
(k10 + k12 + k13)V1C1[n]  k21V2C2[n]  k31V3C3[n] (7)
where (7) is subject to the constraints (5) and
CE[n+ 1] = C1[n+ 1] = CT (8a)
CE[n+ 2] = C1[n+ 2] = CT (8b)
The value IR[n] that is solution of the effect site TCI problem
depends on the current process status C1[n], C2[n], C3[n] and
CE[n]. The flowchart of the solution proposed for the effect
site TCI problem (GALENO-TCI algorithm) is presented in
Fig. 4. This algorithm is used at each sampling time and its
main steps are summarized below:
1) Determine the solution IR[n] using (7);
2) Calculate the predictive C1[n+1] and CE[n+1], using
(2);
3) Calculate the predictive C1[n + 2] and CE[n + 2],
assuming IR[n+ 1] = 0, using (2);
4) IR[n] is considered a valid input, satisfying (8), if
C1[n+ 2]  CE[n+ 2];
5) Otherwise (if C1[n+2] > CE[n+2]), re-calculate IR[n]
using the recursive iterative method described below:
Numerical iterative method: This iterative procedure for
calculating IR[n] is only used in the case of C1[n + 2] >
CE[n + 2], meaning that the problem not be solved in
one sampling time. This fact is not a drawback, since the
constraints (8) may be reformulated by introducing p sampling
time, where p = 1, 2, 3, ..., as
CE[n+ p] = C1[n+ p] = CT (9a)
CE[n+ p+ 1] = C1[n+ p+ 1] = CT (9b)
This procedure searches for a solution satisfying (9) and
minimizing p. It is based in the iterative method represented
End
IR[n] satisfies (8)
Numeric Solution
(to find IR[n] (Fig. 5))
C1[n + 2]  CE[n + 2] NoYes
[C1[n + 2], CE[n + 2]] =
Model(C1[n + 1], C2[n + 1], C3[n + 1], CE[n + 1], 0) (2)
[C1[n + 2], CE[n + 2]] =
Model(C1[n], C2[n], C3[n], CE[n], IR[n]) (2)
Determine IR[n] (7)
GALENO TCI
(C1[n], C2[n], C3[n], CE[n], Model, IRmax)
Fig. 4: Flowchart of GALENO-TCI for effect site concentra-
tion.
in Fig. 5. This procedure is a practical and straightforward
criterion based on the hardware constrains, e.g. the ALARIS
GH syringe pump has infusion rate range between 0 and 1200
ml/h, with increment of 0.1 ml/h; thus after 15 iterations
1200/215 = 0.036 < 0.1 is obtained. Figure 6 shows the
performance of the GALENO-TCI for propofol using the
Schnider’s model [7]. The upper plot of Fig. 6 shows the effect
site concentration CE, in thick solid line, reaching the target
effect site concentration CT, represented by the line with dots,
as desired. The concentration of the drug (propofol) in the
plasma is represented by C1, in thin solid line. This regulation
is due to the administered infusion IR, in the bottom plot of
Fig. 6.
B. Maintenance phase
The practical experience achieved in the GALENO project
[12] over 350 clinical trials suggest that the ideal time to
enable the automatic controller for the NMB is after the
spontaneous recovery of NMB after the initial bolus. This time
instant is usually determined by the ”OnLine tuned Algorithm
for Recovery Detection” [13]. Similarly, experience suggests
that the ideal time to enable the automatic controllers for the
DoA is after completion of the induction phase, when the BIS
reaches a value that is close to the desired reference.
1) Control of neuromuscular blockade: One of the con-
trollers that are implemented in the GALENO Platform for
the control of the NMB after recovery from the initial bolus
is a self-calibrating total-mass controller for the NMB based
on the minimally parameterized parsimonious Wiener model
described in detail in [14]. The idea behind it is that, by the
use of the parameters of the model [15] describing the effect
of muscle relaxants in the NMB that are on-line identified by
an extended Kalman Filter (EKF), the total mass of muscle
relaxant in the different compartments of the human body
EndIR1 = IR IR2 = IR
CEp < CT
No Yes
Cont = 0
No Yes
Cont = Cont  1
CEp = CT
No Yes
IR = (IR1 + IR2)/2
C1p > CEp
Yes No
IR = 0
[C1p, C2p, C3p, CEp] = Model(C1p, C2p, C3p, CEp, IR)
IR = (IR1 + IR2)/2
C1p = C1; C2p = C2; C3p = C3; CEp = CE
IR1 = 0; IR2 = IRmax; Cont = 15
Numerical Solution
(C1, C2, C3, CE, Model, IRmax)
Fig. 5: Flowchart of successive approximations method used
in GALENO-TCI.
0 5 10 15
0
10
20
Co
nc
en
tra
tio
n 
[µ 
g/
m
l] GALENO−TCI (Effect site concentration for propofol)
 
 
C1
CE
CT
0 5 10 15
0
1
2
x 105
IR
 [µ
 
g/
m
in
]
Time [min]
Fig. 6: Performance of GALENO-TCI for propofol admin-
istration using Schnider’s model. CT is the target effect site
concentration, C1 is the plasma concentration and CE is the
effect concentration.
can be controlled [16] so that the measured TOF T1 response
follows a predefined set-point (usually 5-10%).
2) Control of depth of anesthesia: The scheduled strategy
to control the DoA uses the hypnotic and the analgesic drug as
control variables. The hypnotic drug administration (propofol)
is controlled with a cascade of a closed-loop GALENO-TCI
and a proportional integral (PI) controller [2]. The analgesic
drugs administration (remifentanil or sufentanil) is controlled
with the open-loop GALENO-TCI.
The premise used to develop the closed-loop GALENO-
TCI-PI is based on the assumption that in a real patient,
2.5min after a step change on the TCI reference, the drug
concentration at the effect site CE[n] reaches steady state.
The GALENO-TCI block has a fixed sampling time (TsTCI )
of 5 seconds and calculates the infusion rate of propofol
that should be given to the patient so that the effect site
target concentration is reached. The PI block has a variable
sampling time (2.5  TsPI   5min) and determines the effect
site target concentration (CT ) that tracks the BIS reference
(BISref ) using
CT [n+ 1] = CT [n] +
1
kp
(BISref  BIS[n]), (10)
where kp is a proportional gain that was empirically assumed
as equal to kp =  10.
IV. RESULTS
The amTIVA described in section II-B comprising the
GALENO-TCI, and the NMB and the DoA controllers de-
scribed in section III, was successfully validated in more than
thirty patients undergoing general anesthesia.
Figures 7, 8 and 9 illustrate the performance of
the amTIVA for three cases with different anesthetic
drug combinations: rocuronium/propofol/remifentanil, rocuro-
nium/propofol/sufentanil and rocuronium/propofol/fentanil,
respectively.
The GALENO-TCI algorithm described in section III-A2
was used during induction for both propofol, sufentanil and
remifentanil, using models from [7], [8] and [9], respectively.
During maintenance of propofol administration, the
GALENO-TCI-PI algorithm, described in section III-B2 was
used.
For the case shown in Fig. 9 fentanil was administrated
manually by bolus (see bottom plot of Fig. 9).
In all clinical trials the controlled variables (NMB and BIS)
remained close to the respective references (NMBref = 5%
and BISref = 50%), maintaining an relative error less than
5%, which is clinically accepted in anesthetic practice. The
controlled variables are shown in the two upper plots of Figs.
7, 8, and 9. Moreover, the administered drug rates are in
accordance with the guidelines.
V. CONCLUSION
The great challenge of complete automation of drug ad-
ministration in anesthesia is overcome using the amTIVA
proposed in this paper. This is shown for a variety of drugs
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Fig. 7: Performance of the amTIVA in a real
case of general anesthesia. Anesthetic drugs:
rocuronium/propofol/remifentanil.
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Fig. 9: Performance of the amTIVA in a real case of general
anesthesia. Anesthetic drugs: rocuronium/propofol/fentanil.
and administration protocols. The cascade of a closed-loop
GALENO-TCI and a PI controller for DoA with propofol
[2] is able to maintain the BIS index within the clinically
recommended range, even responding well to unexpected
disturbances and measurement noise. At the same time, the
adaptive controller based on a minimally parameterized par-
simonious Wiener model for the rocuronium induced NMB
achieved satisfactory tracking of the NMB reference, and the
on-line identification of parameters ensures the decrease of the
patient model uncertainties.
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